ADAMTS13 and thrombotic thrombocytopenic purpura: Several studies have explored the use of intermediate-purity factor VIII concentrates for both treatment and prophylaxis in congenital TTP, as certain commercially available products have been shown to contain high amounts of ADAMTS13.